Loading
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Previous close
$108.32
−$0.47 · -0.43%
Regular session · ET · Market data may be delayed.
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Day range
Current $108.32
52-week range
Current $108.32
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Buy
Favorable setup — positive multi-factor alignment
Valuation
83
Deep Value
Sentiment
72
Bullish
Risk
31
Moderate Risk
Momentum
38
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Day range
Current $108.32
52-week range
Current $108.32
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 44.33B USD | 41.95B USD | 40.11B USD | 43.65B USD | 43.08B USD |
| Cost of goods sold | 19.72B USD | 20.63B USD | 20.07B USD | 21.33B USD | 19.86B USD |
| Gross profit | 24.61B USD | 21.33B USD | 20.04B USD | 22.32B USD | 23.21B USD |
| Research and development | 2.96B USD | 2.82B USD | 2.72B USD | 2.85B USD | 2.74B USD |
| Selling, general, and administrative | 12.38B USD | 11.65B USD | 10.88B USD | 11.11B USD | 11.28B USD |
| Operating expenses | 16.59B USD | 14.47B USD | 13.6B USD | 13.96B USD | 14.01B USD |
| Interest income | 230M USD | 344M USD | 385M USD | 183M USD | 43M USD |
| Interest expense | 341M USD | 603M USD | 698M USD | 315M USD | 410M USD |
| Depreciation and amortization | 2.75B USD | 3.22B USD | 3.24B USD | 3.27B USD | 3.54B USD |
| Operating income | 8.05B USD | 6.83B USD | 6.44B USD | 8.36B USD | 9.2B USD |
| Net income | 6.52B USD | 13.4B USD | 5.72B USD | 6.93B USD | 7.07B USD |
Company facts updated Sep 5, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI5.86B0.25%2.3T USD0.03%$379.73-0.32%
Schwab U.S. Dividend Equity ETFSCHD5.19B4.61%112.94B USD0.06%$34.80-0.80%
Vanguard S&P 500 ETFVOO4.83B0.29%1.7T USD0.03%$708.01-0.38%
iShares Core S&P 500 ETFIVV2.52B0.29%878.68B USD0.03%$773.92-0.41%
State Street SPDR S&P 500 ETFSPY2.32B0.28%817.33B USD0.09%$770.19-0.39%
Vanguard Morningstar Value ETFVTV1.75B0.68%256.5B USD0.03%$226.46-0.25%
State Street Health Care Select Sector SPDR ETFXLV1.37B3.03%45.09B USD0.08%$171.45-1.04%
Vanguard Dividend Appreciation ETFVIG1.04B0.79%130.9B USD0.04%$242.02-0.46%Vanguard Morningstar Total Stock Market ETFVTISchwab U.S. Dividend Equity ETFSCHDVanguard S&P 500 ETFVOOiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Value ETFVTVState Street Health Care Select Sector SPDR ETFXLVVanguard Dividend Appreciation ETFVIGAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
